Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcysteine SCHEMBL4433757 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3923962 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3923959 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437350 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL5292 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL149212 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL3688241 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL5291 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4437351 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4433756 | 1.00 | MAPT (1.00) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 652 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2026-05-26 | — | — | US | claimed |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-01-27 | — | — | US | claimed |
| US-12486178-B2 | Copper nanoclusters, composition comprising the same, and treatment of multiple sclerosis | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-12-02 | — | — | US | claimed |
| US-20250249036-A1 | Composition and Method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2025-08-07 | — | — | US | claimed |
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2025-07-29 | — | — | US | claimed |
| CN-120192252-A | Synthesis method of key intermediate of itracin | 安徽峆一药业股份有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-12310985-B2 | Composition and method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY (CN) | 2025-05-27 | — | — | US | claimed |
| CN-119899242-A | Method for producing AMG416 | 美国安进公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119874825-A | Method for producing AMG416 | 美国安进公司 | 2025-04-25 | — | — | CN | claimed |
| CN-114524860-B | ETELCALCETIDE synthesis method and application thereof | 深圳翰宇药业股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20040171682-A1 | Drugs for chronic pains | NICOX S.A. (FR) | 2004-09-02 | — | — | US | claimed |
| US-20030141260-A1 | Oxygen-enhanced pathogen inactivation | GAMBRO, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003057253-A1 | OXYGEN-ENHANCED PATHOGEN INACTIVATION | GAMBRO, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| CN-1424900-A | Topical skin composition | TONDAR COMMERCIAL GROUP INTERN (US) | 2003-06-18 | — | — | CN | claimed |
| US-20030095959-A1 | Topical skin composition | ACCESS BUSINESS GROUP INTERNATIONAL LLC. | 2003-05-22 | — | — | US | claimed |
| US-5728373-A | EXHIBITING DEEP SKIN PENETRATION | BEIERSDORF AG (DE) | 1998-03-17 | — | — | US | claimed |
| WO-1997021423-A1 | TOPICAL RETINOID COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-19 | — | — | WO | claimed |
| EP-0656774-B1 | COSMETIC AND DERMATOLOGICAL SUNSCREEN COMPOSITIONS CONTAINING THIOLS AND/OR THIOL DERIVATES | BEIERSDORF AG (DE) | 1997-01-22 | — | — | EP | claimed |
| EP-0138262-B1 | COMPOSITION FOR TREATMENT OF SKIN AFFECTIONS AND ITS APPLICATION | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1990-06-13 | — | — | EP | claimed |
| EP-0138262-A2 | Composition for treatment of skin affections and its application | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1985-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171682-A1 | Drugs for chronic pains | OPRD1, OPRK1, OPRL1 | MAPT 1935/4885KDM4E 4186/4885THRB 1080/4885 |
| US-12371339-B2 | Copper nanoclusters, thymine-modified hyaluronic acid and poly(copper nanoclusters), method for preparing the same, and application thereof | CD44, UMPS, CSGALNACT1 | MAPT 1808/4885KDM4E 4754/4885THRB 846/4885 |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | FABP7, FABP4, LIPC | MAPT 801/4885KDM4E 4588/4885THRB 75/4885 |
| US-20030095959-A1 | Topical skin composition | CUTA, S100A4, KRT18 | MAPT 1787/4885KDM4E 4634/4885THRB 3415/4885 |
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | FABP1, ALB, CSTB | MAPT 2527/4885KDM4E 4638/4885THRB 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.